Inhibrx Biosciences (INBX) Competitors

$103.12 -3.73 (-3.49%)

As of 12:20 PM Eastern

INBX vs. CNTA, SRRK, PTCT, CGON, and COGT

Should you buy Inhibrx Biosciences stock or one of its competitors? MarketBeat compares Inhibrx Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibrx Biosciences include Centessa Pharmaceuticals (CNTA), Scholar Rock (SRRK), PTC Therapeutics (PTCT), CG Oncology (CGON), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Inhibrx Biosciences compare to Centessa Pharmaceuticals?

Inhibrx Biosciences (NASDAQ:INBX) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Centessa Pharmaceuticals' return on equity of -60.37% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Inhibrx Biosciences presently has a consensus price target of $150.00, indicating a potential upside of 44.68%. Centessa Pharmaceuticals has a consensus price target of $40.70, indicating a potential upside of 2.33%. Given Inhibrx Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Inhibrx Biosciences is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Inhibrx Biosciences has a beta of 3.88, meaning that its share price is 288% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

In the previous week, Inhibrx Biosciences had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 1 mentions for Inhibrx Biosciences and 0 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.00 beat Inhibrx Biosciences' score of -0.63 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibrx Biosciences	Negative
Centessa Pharmaceuticals	Neutral

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 17.1% of Inhibrx Biosciences shares are held by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inhibrx Biosciences has higher earnings, but lower revenue than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,170.07	-$140.05M	-$8.39	N/A
Centessa Pharmaceuticals	$15M	395.71	-$197.53M	-$1.79	N/A

Summary

Inhibrx Biosciences beats Centessa Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Scholar Rock?

Inhibrx Biosciences (NASDAQ:INBX) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Inhibrx Biosciences presently has a consensus target price of $150.00, indicating a potential upside of 44.68%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 11.01%. Given Inhibrx Biosciences' higher probable upside, equities analysts clearly believe Inhibrx Biosciences is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 17.1% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Inhibrx Biosciences has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,170.07	-$140.05M	-$8.39	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Scholar Rock's return on equity of -163.52% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Scholar Rock	N/A	-163.52%	-96.67%

In the previous week, Scholar Rock had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Scholar Rock and 1 mentions for Inhibrx Biosciences. Scholar Rock's average media sentiment score of 0.59 beat Inhibrx Biosciences' score of -0.63 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has a beta of 3.88, indicating that its share price is 288% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Summary

Scholar Rock beats Inhibrx Biosciences on 8 of the 15 factors compared between the two stocks.

How does Inhibrx Biosciences compare to PTC Therapeutics?

Inhibrx Biosciences (NASDAQ:INBX) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Inhibrx Biosciences presently has a consensus price target of $150.00, indicating a potential upside of 44.68%. PTC Therapeutics has a consensus price target of $89.00, indicating a potential upside of 26.00%. Given Inhibrx Biosciences' higher possible upside, equities analysts clearly believe Inhibrx Biosciences is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

PTC Therapeutics has higher revenue and earnings than Inhibrx Biosciences. PTC Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,170.07	-$140.05M	-$8.39	N/A
PTC Therapeutics	$1.73B	3.39	$682.64M	-$2.33	N/A

Inhibrx Biosciences has a beta of 3.88, suggesting that its stock price is 288% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Inhibrx Biosciences has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. PTC Therapeutics' return on equity of -362.45% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

In the previous week, PTC Therapeutics had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for PTC Therapeutics and 1 mentions for Inhibrx Biosciences. PTC Therapeutics' average media sentiment score of 1.37 beat Inhibrx Biosciences' score of -0.63 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
PTC Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.5% of Inhibrx Biosciences shares are held by institutional investors. 17.1% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

PTC Therapeutics beats Inhibrx Biosciences on 9 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CG Oncology presently has a consensus price target of $81.73, indicating a potential upside of 34.20%. Inhibrx Biosciences has a consensus price target of $150.00, indicating a potential upside of 44.68%. Given Inhibrx Biosciences' higher possible upside, analysts plainly believe Inhibrx Biosciences is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

CG Oncology's return on equity of -23.33% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

In the previous week, CG Oncology had 1 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 2 mentions for CG Oncology and 1 mentions for Inhibrx Biosciences. CG Oncology's average media sentiment score of -0.04 beat Inhibrx Biosciences' score of -0.63 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Inhibrx Biosciences has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$5.07M	1,059.22	-$160.99M	-$2.33	N/A
Inhibrx Biosciences	$1.30M	1,170.07	-$140.05M	-$8.39	N/A

CG Oncology has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.88, indicating that its share price is 288% more volatile than the broader market.

Summary

CG Oncology and Inhibrx Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Cogent Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Inhibrx Biosciences has a beta of 3.88, suggesting that its share price is 288% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Cogent Biosciences' return on equity of -104.27% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Cogent Biosciences	N/A	-104.27%	-54.64%

In the previous week, Cogent Biosciences had 1 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Inhibrx Biosciences. Cogent Biosciences' average media sentiment score of 0.67 beat Inhibrx Biosciences' score of -0.63 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,170.07	-$140.05M	-$8.39	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

82.5% of Inhibrx Biosciences shares are held by institutional investors. 17.1% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Inhibrx Biosciences currently has a consensus target price of $150.00, indicating a potential upside of 44.68%. Cogent Biosciences has a consensus target price of $43.73, indicating a potential upside of 28.35%. Given Inhibrx Biosciences' higher probable upside, research analysts plainly believe Inhibrx Biosciences is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Cogent Biosciences beats Inhibrx Biosciences on 8 of the 15 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INBX vs. The Competition

Export

Metric	Inhibrx Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.51B	$3.39B	$6.40B	$12.46B
Dividend Yield	N/A	2.26%	2.76%	5.27%
P/E Ratio	-12.29	18.95	20.85	25.92
Price / Sales	1,170.07	194.82	526.06	69.57
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-72.50	7.18	10.46	7.16
Net Income	-$140.05M	$24.25M	$3.56B	$336.99M
7 Day Performance	-5.75%	5.04%	3.11%	3.36%
1 Month Performance	-21.13%	4.11%	2.64%	3.50%
1 Year Performance	689.64%	65.98%	36.39%	36.16%

Inhibrx Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INBX Inhibrx Biosciences	2.3052 of 5 stars	$103.12 -3.5%	$150.00 +45.5%	+730.9%	$1.51B	$1.30M	N/A	166
CNTA Centessa Pharmaceuticals	1.5216 of 5 stars	$39.78 +0.1%	$40.70 +2.3%	+209.1%	$5.93B	$15M	N/A	200
SRRK Scholar Rock	2.1079 of 5 stars	$51.51 +7.0%	$56.00 +8.7%	+71.7%	$5.77B	N/A	N/A	140	High Trading Volume
PTCT PTC Therapeutics	3.7155 of 5 stars	$67.65 -1.7%	$88.36 +30.6%	+47.3%	$5.71B	$1.73B	N/A	1,410	Positive News Analyst Upgrade
CGON CG Oncology	2.8018 of 5 stars	$61.89 -3.7%	$81.73 +32.1%	+143.3%	$5.67B	$4.04M	N/A	61	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INBX) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibrx Biosciences (INBX) Competitors

INBX vs. CNTA, SRRK, PTCT, CGON, and COGT

How does Inhibrx Biosciences compare to Centessa Pharmaceuticals?

Summary

How does Inhibrx Biosciences compare to Scholar Rock?

Summary

How does Inhibrx Biosciences compare to PTC Therapeutics?

Summary

How does Inhibrx Biosciences compare to CG Oncology?

Summary

How does Inhibrx Biosciences compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibrx Biosciences (INBX) Competitors

INBX vs. CNTA, SRRK, PTCT, CGON, and COGT

How does Inhibrx Biosciences compare to Centessa Pharmaceuticals?

Is INBX or CNTA more profitable?

Do analysts prefer INBX or CNTA?

Which has more risk & volatility, INBX or CNTA?

Does the media refer more to INBX or CNTA?

Do institutionals & insiders believe in INBX or CNTA?

Which has preferable earnings and valuation, INBX or CNTA?

Summary

How does Inhibrx Biosciences compare to Scholar Rock?

Do analysts recommend INBX or SRRK?

Do institutionals and insiders have more ownership in INBX or SRRK?

Which has stronger earnings & valuation, INBX or SRRK?

Is INBX or SRRK more profitable?

Does the media favor INBX or SRRK?

Which has more risk & volatility, INBX or SRRK?

Summary

How does Inhibrx Biosciences compare to PTC Therapeutics?

Do analysts rate INBX or PTCT?

Which has stronger valuation and earnings, INBX or PTCT?

Which has more volatility and risk, INBX or PTCT?

Is INBX or PTCT more profitable?

Does the media favor INBX or PTCT?

Do institutionals & insiders have more ownership in INBX or PTCT?

Summary

How does Inhibrx Biosciences compare to CG Oncology?

Do institutionals and insiders believe in CGON or INBX?

Do analysts rate CGON or INBX?

Is CGON or INBX more profitable?

Does the media refer more to CGON or INBX?

Which has preferable valuation and earnings, CGON or INBX?

Which has more volatility & risk, CGON or INBX?

Summary

How does Inhibrx Biosciences compare to Cogent Biosciences?

Which has more risk and volatility, INBX or COGT?

Is INBX or COGT more profitable?

Does the media favor INBX or COGT?

Which has higher valuation & earnings, INBX or COGT?

Do insiders and institutionals have more ownership in INBX or COGT?

Do analysts rate INBX or COGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools